Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Colorectal Cancer · Microsatellite Instability High

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651, Guangzhou, Guangdong, China
Contact: Study coordinator (Bin-Yi Xiao, M.D.) · xiaoby@sysucc.org.cn · +86-15800004780
Contact: Study coordinator (Pei-Rong Ding, M.D.)

Study leads

Pei-Rong Ding, M.D.
Principal Investigator
Sun Yat-Sen University Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Metastatic Colorectal Adenocarcinoma · Stage IV Colorectal Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE3

Kingman, United States · Phoenix, United States

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Colorectal Cancer · Liver Metastases

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Rectal Cancer

Abroad (travel likely)RecruitingPHASE2

Richmond, United States · Richmond, United States

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Colorectal Cancer (Diagnosis) · Colorectal Cancer Metastatic · Colorectal Cancer (CRC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Liverpool, Australia · Macquarie Park, Australia